Jansen Kristina, Kornfeld Lara, Lennartz Maximilian, Dwertmann Rico Sebastian, Kind Simon, Reiswich Viktor, Viehweger Florian, Bawahab Ahmed Abdulwahab, Fraune Christoph, Gorbokon Natalia, Luebke Andreas M, Hube-Magg Claudia, Menz Anne, Uhlig Ria, Krech Till, Hinsch Andrea, Jacobsen Frank, Burandt Eike, Sauter Guido, Simon Ronald, Kluth Martina, Steurer Stefan, Marx Andreas H, Clauditz Till S, Dum David, Lebok Patrick, Minner Sarah, Bernreuther Christian
Department of General, Visceral, and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
Cancers (Basel). 2024 Dec 3;16(23):4052. doi: 10.3390/cancers16234052.
BACKGROUND/OBJECTIVES: Carcinoembryonic antigen (CEA) is a cell-surface glycoprotein serving as a drug target, diagnostic marker, and serum marker for cancer monitoring. However, prevalence data on CEA expression in cancer tissues vary considerably. This study was designed to determine CEA expression in normal and neoplastic tissues.
A tissue microarray containing 13,725 samples from 120 different tumor types, as well as 76 different normal tissue types, was analyzed by immunohistochemistry (IHC).
CEA was detectable in 65 (54.2%) of 120 tumor categories, including 49 (40.8%) tumor types with at least one strongly positive case. CEA positivity was most common in colorectal adenomas (100%) and carcinomas (98.7%), other gastrointestinal adenocarcinomas (61.1-80.3%), medullary carcinomas of the thyroid (96.3%), pulmonary adenocarcinoma (73.7%), mucinous carcinomas of the ovary (79.8%) and the breast (43.2%), small-cell carcinomas of the lung (64.3%), and urinary bladder (38.9%). CEA overexpression was linked to high tumor grade and invasive growth ( < 0.0001 each) in urinary bladder cancer, and estrogen and HER2 receptor positivity ( ≤ 0.0158) in invasive breast cancer of no special type. In colorectal adenocarcinomas, reduced CEA expression was associated with mismatch repair deficiency ( < 0.0001).
The comprehensive list of CEA-positive human tumor types demonstrates that CEA is expressed in a broad range of epithelial neoplasms, many of which might benefit from CEA serum monitoring and anti-CEA therapies.
背景/目的：癌胚抗原（CEA）是一种细胞表面糖蛋白，可作为药物靶点、诊断标志物以及癌症监测的血清标志物。然而，关于癌组织中CEA表达的流行率数据差异很大。本研究旨在确定正常组织和肿瘤组织中CEA的表达情况。
采用免疫组织化学（IHC）方法分析了一个组织芯片，该芯片包含来自120种不同肿瘤类型的13725个样本以及76种不同正常组织类型的样本。
在120种肿瘤类别中，有65种（54.2%）可检测到CEA，其中49种（40.8%）肿瘤类型至少有1例强阳性病例。CEA阳性在结直肠腺瘤（100%）和癌（98.7%）、其他胃肠道腺癌（61.1 - 80.3%）、甲状腺髓样癌（96.3%）、肺腺癌（73.7%）、卵巢黏液性癌（79.8%）和乳腺癌（43.2%）、肺小细胞癌（64.3%）以及膀胱癌（38.9%）中最为常见。在膀胱癌中，CEA过表达与高肿瘤分级和浸润性生长相关（均P<0.0001），在非特殊类型的浸润性乳腺癌中与雌激素和HER2受体阳性相关（P≤0.0158）。在结直肠腺癌中，CEA表达降低与错配修复缺陷相关（P<0.0001）。
CEA阳性人类肿瘤类型的综合列表表明，CEA在广泛的上皮性肿瘤中表达，其中许多肿瘤可能受益于CEA血清监测和抗CEA治疗。
